Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $6.4 million.

  • Pulmonx's Accounts Payables rose 4029.72% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 4029.72%. This contributed to the annual value of $3.8 million for FY2024, which is 15564.46% up from last year.
  • As of Q3 2025, Pulmonx's Accounts Payables stood at $6.4 million, which was up 4029.72% from $6.6 million recorded in Q2 2025.
  • Pulmonx's Accounts Payables' 5-year high stood at $6.6 million during Q2 2025, with a 5-year trough of $1.5 million in Q4 2023.
  • For the 5-year period, Pulmonx's Accounts Payables averaged around $3.2 million, with its median value being $2.9 million (2023).
  • As far as peak fluctuations go, Pulmonx's Accounts Payables tumbled by 4027.97% in 2022, and later surged by 15564.46% in 2024.
  • Quarter analysis of 5 years shows Pulmonx's Accounts Payables stood at $1.6 million in 2021, then grew by 11.13% to $1.8 million in 2022, then dropped by 14.85% to $1.5 million in 2023, then surged by 155.64% to $3.8 million in 2024, then skyrocketed by 67.76% to $6.4 million in 2025.
  • Its Accounts Payables stands at $6.4 million for Q3 2025, versus $6.6 million for Q2 2025 and $4.3 million for Q1 2025.